The four key mechanisms: Brain appetite centers: Reduces food noise the constant mental preoccupation with food and cravings that many patients describe as their biggest challenge Gastric emptying: Slows how quickly food leaves the stomach, producing prolonged fullness after smaller meals Insulin response: Stimulates insulin release when blood sugar rises improving glucose management without causing low blood sugar on its own Glucagon suppression: Reduces glucagon, a hormone that signals the liver to release stored sugar unnecessarily 2
GLP-1 can disrupt your gut microbiome leading to diarrhea, consitpation, bloating, and abdominal pain
Originally developed to improve glycemic control in type 2 diabetes, drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have proven remarkably effective at helping patients lose weight
Body weight reduction averaged 5.5% in the liraglutide arm compared to 0.7% with placebo ( P = 0.003), while glycemic control improved as reflected by a mean HbA1c decrease of 5.7 mmol/mol ( P = 0.03)
2020;105(8):e2710e2716
While no longer in short supply meaning that compounding should no longer be possible some companies have continued to provide the drug to patients under exceptions for 'personalised' treatments under a framework known as Section 503A